Enlarged prostate<unk>  is used for treating benign prostatic hyperplasia (BPH); colloquially known as an "enlarged prostate". It is approved by the Food and Drug Administration (FDA) in the U.S. for this indication. Prostate cancer A 2010 Cochrane review found a 25–26% reduction in the risk of developing prostate cancer with 5α-reductase inhibitor chemoprevention. However, 5α-reductase inhibitors have been found to increase the risk of developing certain rare but aggressive forms of prostate cancer (27% risk increase), although not all studies have observed this. There is insufficient data to determine if they have an effect on the overall risk of death from prostate cancer. Scalp hair loss<unk>  is approved for the treatment of male androgenetic alopecia in South Korea and Japan at a dosage of 0.5 mg per day. It has been found in several studies to induce hair regrowth in men more rapidly and to a greater extent than even the highest approved dosage of finasteride. The superior effectiveness of<unk>  relative to finasteride for this indication is related to the fact that the inhibition of 5α-reductase and consequent reduction of DHT production within the hair follicles is more complete with<unk> .<unk>  is also used off-label in the treatment of female pattern hair loss. Excessive hair growth Although no reports specific to<unk>  currently exist, 5α-reductase inhibitors like finasteride have been found to be effective in the treatment of hirsutism (excessive facial and/or body hair growth) in women. In a study of 89 women with hyperandrogenism due to persistent adrenarche syndrome, finasteride produced a 93% reduction in facial hirsutism and a 73% reduction in bodily hirsutism after 2 years of treatment. Other studies using finasteride for hirsutism have also found it to be clearly effective.<unk>  may be more effective than finasteride for this indication due to the fact that its inhibition of the 5α-reductase enzyme is comparatively more complete. Transgender hormone therapy<unk>  is sometimes used as a component of hormone therapy for transgender women in combination with an estrogen and/or another antiandrogen like spironolactone. It may be useful for treating scalp hair loss or in those who have issues tolerating spironolactone. Available forms<unk>  is provided in the form of soft oil-filled gelatin oral capsules containing 0.5 mg<unk>  each.
Dutasteride
Finasteride
Tadalafil
Ingenol mebutate
Tamsulosin
Cyproterone acetate
Alclometasone
Vardenafil